Drug intelligence / Profile preview

[161Tb] PSMA I&T

Development stage: Unknown
Lead developer: PET Pharm Biotech
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

[161Tb] PSMA I&T (PPhB-Tb01) is a next-generation radioligand therapy developed by PET Pharm Biotech for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug consists of the PSMA I&T (Imaging and Therapy) peptide ligand, which specifically targets the prostate-specific membrane antigen (PSMA) overexpressed on prostate cancer cells, labeled with the radioisotope terbium-161 (161Tb). Terbium-161 is a potent therapeutic radionuclide that emits both beta particles and a high density of short-range Auger and conversion electrons. This dual emission profile potentially offers enhanced therapeutic efficacy compared to lutetium-177 by delivering a higher radiation dose to small clusters of tumor cells and micrometastases while sparing surrounding healthy tissue. The program is currently in Phase 1 clinical development.

Other names: [161Tb]PSMA-I&T161Tb-PSMA-I&Tterbium-161 PSMA I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on [161Tb] PSMA I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [161Tb] PSMA I&T.

Explore the full profile